Deals this week: IBM Research-Australia, Cure Forward, Agilis Biotherapeutics

30th June 2016 (Last Updated June 30th, 2016 18:30)

IBM Research-Australia and Melanoma Institute Australia have entered a research agreement to further pursue research on the identification of early stages of melanoma using cognitive technology.

IBM Research

IBM Research-Australia and Melanoma Institute Australia have entered a research agreement to further pursue research on the identification of early stages of melanoma using cognitive technology.

Pursuant to the agreement, IBM Research-Australia will analyse dermatological images of skin lesions, while Melanoma Institute Australia will help to reduce biopsies and to accurately identify the clinical patterns in early stages of melanoma.

With the help of Melanoma Institute Australia and Mole Map, IBM Research-Australia will further train and validate algorithms to understand and identify early stages of skin cancer and improve patient care.

Cure Forward has entered a partnership with Novartis Pharmaceuticals to advance its real-time patient sourcing in clinical trials to further expand innovative treatments.

According to the agreement, Cure Forward will support Novartis in sourcing potential patients for all the current oncology trials through its clinical trial exchange.

Agilis Biotherapeutics and National Cancer for Accelerating Translation Sciences (NCATS) have entered a co-operative research and development agreement (CRADA) to further develop Agilis' gene therapy treatment for Aromatic L-Amino Acid Decarboxylase (AADC) deficiency.

According to the agreement, the two partners will jointly develop Agilis' gene therapy candidate, conduct toxicology, process development and manufacturing, and development of gene therapy, as well as work on registration process in the US and other countries.

Mayne Pharma has announced pro-rata accelerated, non-renounceable rights offering of its 469,529,085 shares to raise gross proceeds of $444.5m.

"Mayne Pharma has announced pro-rata accelerated, non-renounceable rights offering of its 469,529,085 shares to raise gross proceeds of $444.5m."

Credit Suisse (Australia) Limited and UBS AG, Australia Branch are acting as underwriters for the offering.

The company plans to invest the funds for the acquisition of US generic products portfolio from Teva Pharma and Allergan, for cost associated with transfer of products to its facilities and contract manufacturing organisations, and also to purchase equipment and support in-house manufacturing for its facilities in Greenville, North Carolina and South Australia.

Bio pharmaceutical company Icagen Inc. has entered a definitive agreement with Sanofi to acquire its ultra-high throughput biology, screening and chemistry capabilities, and research facility in Oro Valley, in order to expand its integrated drug discovery services in a growing market.

According to the agreement, Icagen will be responsible to manage an extensive Sanofi compound library, making it available to all its partners and increasing the potential of drug discovery.


Image: IBM Research-Australia and Melanoma Institute Australia have entered a research agreement. Photo: Courtesy of Simon Greig.